Investigator-led study funded by Glaucoma UK and the HSC R&D Division expands ART27.13’s clinical potential into ophthalmology

Initial DREAM Study Results Anticipated in Q4 2026

SOLANA BEACH, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced the first patient has been dosed in the DREAM study (Determining the Role of synthetic cannabinoids in Eye pressure And tolerability Measurements), which will evaluate the effects of Artelo’s orally administered synthetic cannabinoid, ART27.13, in patients with glaucoma or ocular hypertension.

ART27.13, a peripherally selective synthetic cannabinoid receptor agonist, represents a novel therapeutic approach aimed at modulating intraocular pressure (IOP) through activation of cannabinoid receptors located in ocular tissues.

Funding for the DREAM study is being provided by Glaucoma UK and the HSC R&D Division. The study is sponsored by the Belfast Health and Social Care Trust and is being conducted by the Northern Ireland Clinical Trials Unit. Clinical Professor of Ophthalmology at Queen’s University Belfast and Honorary Consultant Ophthalmologist at Belfast Health and Social Care Trust, Professor Augusto Azuara-Blanco, a globally recognized authority in glaucoma management and clinical research, is leading the DREAM study.